Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
2
50%
Ph phase_2
2
50%

Phase Distribution

0

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 4Post-market surveillance
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Other(2)

Detailed Status

unknown2
Completed1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (50.0%)
Phase 42 (50.0%)

Trials by Status

completed125%
recruiting125%
unknown250%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_4

NeuroAiD Patient-Reported Outcomes in Patients With Mild to Moderate Ischemic Stroke

NCT07828210
unknownphase_4

MLC901 in Moderate Traumatic Brain Injury

NCT04766281
completedphase_2

NEURoaid II (MLC 901) Assessment in Cognitively Impaired Not Demented Subjects

NCT01847924
unknownphase_2

The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study

NCT03038035

Clinical Trials (4)

Showing 4 of 4 trials
NCT07828210Phase 4

NeuroAiD Patient-Reported Outcomes in Patients With Mild to Moderate Ischemic Stroke

Recruiting
NCT04766281Phase 4

MLC901 in Moderate Traumatic Brain Injury

Unknown
NCT01847924Phase 2

NEURoaid II (MLC 901) Assessment in Cognitively Impaired Not Demented Subjects

Completed
NCT03038035Phase 2

The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4